Refine by
Cardiac Version Minimct Patient Articles & Analysis
7 articles found
High-performance cardiopulmonary resuscitation (HP-CPR) is a technique that emphasizes delivering chest compressions at the correct depth and rate while avoiding excessive leaning and minimizing interruptions. Often referred to as high-quality CPR within the medical community, HP-CPR is a critical skill that anyone can learn to improve survival outcomes for sudden cardiac arrest (SCA) victims. ...
BACKGROUND: Recent studies have shown that patient-triggered cardiac event recorders (CER) have an increased diagnostic yield and are more cost effective than conventional 24-h-Holter electrocardiograms (ECGs) for the evaluation of sporadic, potentially arrhythmia-related symptoms. HYPOTHESIS: The aim of this study was to determine the diagnostic yield of a patient-triggered CER combined with ...
ByNovacor
BELLEVUE, WA — July 29, 2021– A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambulatory Monitor (CAM) patch was presented at the 2021 Heart Rhythm Society (HRS) Conference. The abstract, “Accelerating Proper Evaluation of Emergency Department Patients for Arrhythmia Concerns with Discharge Use of ECG Patch Monitors,” authored ...
Abstract Purpose: We evaluated Galectin-3 (Gal-3) as a potential early biomarker of acute kidney disease (AKI), and the effect of Gal-3 inhibition by modified citrus pectin (P-MCP) on renal ischemia/reperfusion (I/R) induced AKI. Methods: Among fifty-two post-cardiac surgery patients, serum and urine Gal-3 levels were examined on intensive care unit (ICU) admission. In a rat renal I/R ...
Introduction “Our priority is to provide our customers with the high purity water and steam that is critical to the development and manufacturing of life-saving medications now and for future generations.” —George Gsell, MECO President Nexus Pharmaceuticals, maker of difficult-to-manufacture, high quality, FDA-approved specialty and generic drugs, is opening a $250 million, ...
TAILOR-PCI was a 7-year 5,300-patient clinical trial of precision medicine for cardiac stent patients, funded by Mayo Clinic and the National Institutes of Health (NIH). Genomadix’s FDA-cleared rapid RX CYP2C19 genotyping test was used to personalize antiplatelet therapy with clopidogrel or ticagrelor. The results were published on August 25, 2020 in the Journal of the American Medical ...
Genomadix’s European Scientific Advisory Board Comments on TAILOR-PCI Results *The largest genetics-based clinical trial in cardiology history supported by Genomadix’s Precision Medicine technology * The results of the TAILOR-PCI trial (Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention) were recently ...